The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai Zhongshan Hospital
About this trial
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Eligibility criteria
Qualifiers
Male or female over the age of 18;
First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
Participants should be willing and able to follow the study follow-up plan and other protocol requirements.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Sample of Blood
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov